Price$5.14-0.08 (-1.53%)
01:30 PM07:45 PM
News · 26 weeks60+56%
2026-03-012026-08-23
Mix3490d
- Other11(32%)
- Insider10(29%)
- SEC Filings9(26%)
- Analyst2(6%)
- Leadership1(3%)
- Dividends1(3%)
Latest news
25 items- PRAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on August 10, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). In the aggregate, the three new non-executive employees received options to purchase 287,500 shares of Annexon common stock. The options carry a ten-year term and an exercise price per sha
- SECSEC Form 144 filed by Annexon Inc.144 - Annexon, Inc. (0001528115) (Subject)
- ANALYSTAnnexon upgraded by CitizensCitizens upgraded Annexon from Mkt Underperform to Mkt Perform
- INSIDERSEC Form 4 filed by Director Blumenkranz Mark S.4 - Annexon, Inc. (0001528115) (Issuer)
- INSIDERSEC Form 3 filed by new insider Blumenkranz Mark S.3 - Annexon, Inc. (0001528115) (Issuer)
- SECSEC Form 10-Q filed by Annexon Inc.10-Q - Annexon, Inc. (0001528115) (Filer)
- SECAnnexon Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Annexon, Inc. (0001528115) (Filer)
- PRAnnexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated MilestonesRapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 2026 Vonaprument Phase 3 GA Program Expanded with Month 15 / 24 Dual Primary Endpoint Strategy and Launch of Open-Label Extension Study; Month 15 Primary Endpoint on Track for Q4 2026 POC Data for ANX1502, a First-in-Kind Oral C1 Inhibitor for Autoimmune Disease, Expected in Fall 2026 $200 Million Credit Facility Strengthens Balance Sheet and Capabilities; Anticipated Runway Extended into 2028 Company to Host Business Update Call Today at 8:00 a.m. ET BRISBANE, Calif., A
- PRAnnexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension StudyBRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced the addition of a Month 24 dual primary endpoint to complement the current Month 15 primary endpoint in its Phase 3 ARCHER II trial, and launch of an open-label extension (OLE) study of vonaprument for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). With a dual primary endpoint strategy, ARCHER II can achieve success in protecting against vision loss at either Month 15 or 2
- SECAnnexon Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Annexon, Inc. (0001528115) (Filer)
- PRAnnexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of DirectorsBRISBANE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced the appointment of Mark S. Blumenkranz, M.D., M.M.S., to its board of directors. Dr. Blumenkranz, a renowned retinal surgeon and biotechnology entrepreneur, brings more than four decades of clinical, scientific and corporate leadership experience advancing innovative therapies for retinal disease. The Company also announced that Muneer Satter will step down from the board after more than 11 years of distinguished s
- SECSEC Form SCHEDULE 13G filed by Annexon Inc.SCHEDULE 13G - Annexon, Inc. (0001528115) (Subject)
- SECSEC Form 8-K filed by Annexon Inc.8-K - Annexon, Inc. (0001528115) (Filer)
- PRAnnexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One WeekEarly Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies Potential to Become the First Approved Targeted Therapy to Treat GBS Worldwide, Addressing the Significant Unmet Need and Over $20 Billion Estimated Annual U.S. Healthcare Burden FORWARD Data to Support BLA Submission Targeted for Q4 2026; Tanruprubart Currently Under Review by the EMA BRISBANE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million
- SECAnnexon Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Annexon, Inc. (0001528115) (Filer)
- PRAnnexon Secures Strategic Credit Facility for up to $200 Million from Oxford FinanceBRISBANE, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has entered into a strategic credit facility agreement with Oxford Finance LLC ("Oxford Finance") for up to $200 million. "This strategic facility enhances our financial and operational capabilities as we prepare for the potential global commercialization of vonaprument and tanruprubart, which combined have the potential to reach millions of patients worldwide," said Douglas Love, president and chief execu
- ANALYSTCitizens initiated coverage on Annexon with a new price targetCitizens initiated coverage of Annexon with a rating of Mkt Underperform and set a new price target of $3.00
- PRAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on July 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). In the aggregate, the two new non-executive employees received options to purchase 335,000 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equ
- SECSEC Form 144 filed by Annexon Inc.144 - Annexon, Inc. (0001528115) (Subject)
- PRAnnexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026BRISBANE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced an oral presentation on the neuroprotective effect of vonaprument at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting being held July 15–18, 2026 in Montréal, Québec, Canada. In the Phase 2 ARCHER trial, vonaprument demonstrated significant vision preservation in patients with dry age-related macular degeneration (AMD) with geographic atrophy (GA). An upcoming oral presentation at ASRS
- SECSEC Form 144 filed by Annexon Inc.144 - Annexon, Inc. (0001528115) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Annexon Inc.SCHEDULE 13G/A - Annexon, Inc. (0001528115) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Annexon Inc.SCHEDULE 13G/A - Annexon, Inc. (0001528115) (Subject)
- PRAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on June 13, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). In the aggregate, the two new non-executive employees received options to purchase 705,000 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equ
- INSIDEREVP & CHIEF INNOVATION OFFICER Yednock Ted exercised 30,646 shares at a strike of $1.85, increasing direct ownership by 20% to 184,807 units (SEC Form 4)4 - Annexon, Inc. (0001528115) (Issuer)
ANNX FAQ
7 questionsWhat does Annexon Inc. do?
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; and ANX007, which has completed Phase 1b clinical...Where does ANNX stock trade?
Annexon Inc. (ANNX) is listed on NASDAQ.What sector and industry is ANNX in?
Annexon Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Annexon Inc. go public?
Annexon Inc. (ANNX) completed its IPO in 2020.What are analysts saying about ANNX?
Annexon Inc. has had 8 recent analyst actions on file. The most recent action was from Citizens: Mkt Perform on 2026-08-13.What companies are similar to ANNX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ANNX side-by-side with any of them on Quantisnow.How can I track ANNX on Quantisnow?
Quantisnow aggregates Annexon Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ANNX to receive live email and push alerts on every new disclosure.